Oligodendrogliomas: a short history of clinical developments

Bent, Martin J. van den

doi:10.2217/cns.15.35

Cited by 5 publications

(3 citation statements)

References 32 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 8 ] Moreover, this observation could have arisen secondary to OD-II tumors having earlier treatment with temozolomide than A-mt II, and with A-mt II tumors more likely to undergo postoperative watch-and-wait. [ 31 32 ] Regardless, the finding highlights the utility in stratifying treatments and exclusively examining temozolomide regimens.…”

Section: Discussionmentioning

confidence: 99%

“…[8] Moreover, this observation could have arisen secondary to OD-II tumors having earlier treatment with temozolomide than A-mt II, and with A-mt II tumors more likely to undergo postoperative watch-and-wait. [31,32] daily for 21 days, repeated every 28 days for 12 cycles maximum, PFS was an intermediate value of 36.01 months. [7] Overall survival-World Health Organization, grade II astrocytoma, mutant…”

Section: General Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Role of temozolomide regimen on survival outcomes in molecularly stratified WHO Grade II gliomas: A systematic review

Ghaffari-Rafi

Leon-Rojas

2021

Asian J Neurosurg

View full text Add to dashboard Cite

Objective/Introduction: Although a critical chemotherapeutic, temozolomide's optimal regimen for 2016 World Health Organization (WHO) Grade II gliomas remains elusive, hence there is utility in not only cataloging survival outcomes of Grade II glioma subtypes against the background of temozolomide regimens, but also quantifying differences in progression-free survival (PFS) and overall survival (OS). Materials and Methods: A systematic review of MEDLINE, Embase, and Cochrane Central Register of Controlled Trails was conducted by using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis and the Cochrane Handbook of Systemic Reviews of Interventions. Results: Each molecular subtype of WHO Grade II glioma had a different temozolomide regimen identified as optimal in prolonging PFS and OS. For PFS, with temozolomide, the 25 th , 50 th , and 75 th percentiles, were as follows (in months), respectively–A-wt II: 6.90, 12.95, and 19.95; A-mt II: 34.45, 36.01, and 39.60; OD II: 37.90, 46.00, and 55.03 ( P = 0.016). For OS, the first quartile (25%), median (50%), third quartile (75%), were respectively identified (in months–A-wt II: 21.6 (median; n = 1); A-mt II: 60.6, 85.2, and 109.8; OD II: 86.1, 96.2, and 106.3 ( P = 0.37). Conclusion: For each tumor molecular subtype, a different temozolomide regimen was identified as optimal for prolonging PFS and OS. Furthermore, regardless of temozolomide regimen, A-wt II had a significantly shorter PFS than A-mt II and OD-II. Overall, the data can provide useful prognostic insight to patients when making critical treatment decisions. Moreover, by cataloging and assessing survival outcomes per temozolomide regimen, such may facilitate future clinical trial design.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[8] Moreover, this observation could have arisen secondary to OD-II tumors having earlier treatment with temozolomide than A-mt II, and with A-mt II tumors more likely to undergo postoperative watch-and-wait. [31,32] daily for 21 days, repeated every 28 days for 12 cycles maximum, PFS was an intermediate value of 36.01 months. [7] Overall survival-World Health Organization, grade II astrocytoma, mutant…”

Section: General Considerationsmentioning

confidence: 99%

Role of temozolomide regimen on survival outcomes in molecularly stratified WHO Grade II gliomas: A systematic review

Ghaffari-Rafi

Leon-Rojas

2021

Asian J Neurosurg

View full text Add to dashboard Cite

show abstract

“…Regarding PFS, all three tumor genotypes did have a statistically significant difference between them (Table 2). Finally, the PFS between A-mt II and OD-II was statistically significant (Table 2), with OD-II having a longer median PFS than A-mt II-such is potentially due to OD-II having earlier treatment with chemotherapy and radiotherapy than A-mt II tumors, and A-mt II tumors more likely to receive post-operative watch and scan treatment approach [36,37]…”

Section: Overall Survival-general Considerationsmentioning

confidence: 99%

Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review

Ghaffari-Rafi

Samandouras

2020

World Neurosurgery

View full text Add to dashboard Cite

Objective/IntroductionWith the 2016 update of the WHO Classification of Tumors of the Central Nervous System incorporating molecular subtyping to histology, WHO grade II diffuse astrocytic and oligodendroglial tumors are now subcategorized by distinct molecular markers. Currently, there are no published systematic reviews quantifying differences in progression free survival (PFS) and overall survival (OS) on the basis of molecular subtypes of WHO grade II diffuse gliomas, against the background of administered treatments. MethodsUtilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and the Cochrane Handbook of Systemic Reviews of Interventions, we conducted a systematic review through MEDLINE, Embase, and CENTRAL. ResultsFor OS, the first quartile (25%), median (50%), third quartile (75%), and 95% confidence interval were respectively identified (in months)-astrocytoma-wild type WHO II (

show abstract